Previous studies have reported that positron emission tomography (PET) tracers such as [18F]BMS-986192 and [89Zr]atezolizumab can be used to non-invasively quantify PD-L1 expression in NSCLC tumours in humans [16, 17]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.